Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 683 results

Media Release / May 17, 2018

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
Media Release / May 17, 2018

Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
Media Release / May 12, 2018

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark…
Media Release / May 11, 2018

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Media Release / May 01, 2018

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T…
Media Release / May 01, 2018

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Media Release / May 01, 2018

Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
Media Release / Apr 30, 2018

New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval

- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
Media Release / Apr 30, 2018

New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Media Release / Apr 25, 2018

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable…

‹ Previous page
1
…
30
31
32
33
34
35
36
…
69
› Next page